Phase II Open-Label Pilot Study of V3381 in Chronic Cough
This study has been terminated.
(Lack of efficacy)
Sponsor:
Vernalis (R&D) Ltd
Collaborator:
University Hospital of South Manchester NHS Foundation Trust
Information provided by:
Vernalis (R&D) Ltd
ClinicalTrials.gov Identifier:
NCT01401673
First received: July 21, 2011
Last updated: July 22, 2011
Last verified: July 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The investigators hypothesise that cough reflex hypersensitivity, demonstrated in chronic cough patients, is due to a phenomenon known as central sensitisation. Central sensitisation is a hyper-excitability of the sensory nerves as they join the central nervous system, and is believed to be mediated by the N-Methyl-D-Aspartate (NMDA) receptor[1-3].
| Condition | Intervention | Phase |
|---|---|---|
|
Cough |
Drug: Indantadol |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase II Open-label Pilot Study of V3381, a Novel N-Methyl-D-Aspartate Receptor Antagonist, in Chronic Cough Patients Attending a Specialist Clinic |
Resource links provided by NLM:
Further study details as provided by Vernalis (R&D) Ltd:
Primary Outcome Measures:
- Objective cough frequency at 8 weeks compared to baseline. [ Time Frame: 8 Weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Change in objective cough frequency at 4 weeks. [ Time Frame: 4 Weeks ] [ Designated as safety issue: No ]
- Change in Cough-Specific Quality-of-Life Questionnaire (CQLQ) at 4 and 8 weeks. [ Time Frame: 4 and 8 Weeks ] [ Designated as safety issue: No ]
- Change in Global Rating of Change Scale at 1 week, 2 weeks, 4 weeks and 8 weeks [ Time Frame: 1 Week, 2 Weeks, 4 Weeks and 8 Weeks ] [ Designated as safety issue: No ]
| Enrollment: | 12 |
| Study Start Date: | October 2009 |
| Study Completion Date: | August 2010 |
| Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Drug: Indantadol
Titration
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or female 18-75 years of age
- Females must be of non child-bearing potential
- Chronic Cough ( > 8 weeks)
- Normal Chest X-ray
- Normal Lung Function
- Idiopathic or treatment resistant cough-
Exclusion Criteria:
- Recent upper respiratory tract infection (<4 weeks)
- Pregnancy/breast-feeding
- Current smokers or ex-smokers with <6 months abstinence or cumulative history of >10 pack years
- Current treatment with ACE inhibitors.
- Drug or alcohol abuse
- Uncontrolled hypertension (i.e., >140/90 mmHg despite adequate medical therapy).
- Any cardiovascular condition that would be a contra-indication to the use of sympathomimetic amines (e.g. active angina).
- Any clinically significant neurological disorder
- Prior renal transplant, current renal dialysis.
- Any clinically significant or unstable medical or psychiatric condition that would interfere with the patient's ability to participate in the study.
- Increased risk of seizures.
- Any malignancy in the past 2 years (with the exception of basal cell carcinoma).
- Use of opioids, anticonvulsants, antidepressants (particularly MAO inhibitors).
- Any clinically significant abnormal laboratory test result(s).
- Serum creatinine laboratory value greater than 1.5 x upper limit of normal (ULN) reference range (after adjustment for age) or estimated creatinine clearance <60 mL/min.
- Total bilirubin greater than upper limit of normal reference range (with the exception of Gilbert's Syndrome) and/or alanine transaminase (ALT) >1.5 times upper limit of normal reference ranges (after adjustment for age).
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01401673
Locations
| United Kingdom | |
| South Manchester University Hospital | |
| Manchester, United Kingdom, M23 9LT | |
Sponsors and Collaborators
Vernalis (R&D) Ltd
University Hospital of South Manchester NHS Foundation Trust
Investigators
| Principal Investigator: | Ashley Woodcock, Prof. | South Manchester University Hospital |
More Information
No publications provided
| Responsible Party: | Development Director, Vernalis (R&D) Ltd |
| ClinicalTrials.gov Identifier: | NCT01401673 History of Changes |
| Other Study ID Numbers: | V001 |
| Study First Received: | July 21, 2011 |
| Last Updated: | July 22, 2011 |
| Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Keywords provided by Vernalis (R&D) Ltd:
|
Chronic Cough Indantadol |
Additional relevant MeSH terms:
|
Cough Respiration Disorders Respiratory Tract Diseases Signs and Symptoms, Respiratory Signs and Symptoms N-Methylaspartate |
Excitatory Amino Acid Agonists Excitatory Amino Acid Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 17, 2013